文献速递骨软组织肉瘤与黑色素瘤

曲贝替定在老年肉瘤患者中的疗效与耐受性:III期随机对照研究亚组分析

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究为ET743-SAR-3007的老年亚组分析,纳入131例≥65岁晚期脂肪肉瘤或平滑肌肉瘤患者,随机接受曲贝替定或达卡巴嗪。曲贝替定显著改善无进展生存期(4.9 vs 1.5个月,HR=0.40,P=0.0002),但总生存期和客观缓解率无统计学显著差异,安全性特征与总体人群相当。

要点

  • 老年患者中曲贝替定较达卡巴嗪显著延长无进展生存期(4.9 vs 1.5个月,HR=0.40,P=0.0002)。
  • 总生存期(15.1 vs 8.0个月,HR=0.72,P=0.18)和客观缓解率(9% vs 3%,P=0.43)无统计学显著差异。
  • 曲贝替定组接受≥6周期治疗的比例显著更高(43% vs 23%,P=0.04)。

核心结论

  • 对于体能状态良好的老年软组织肉瘤患者,曲贝替定可带来与年轻患者相似的临床获益。

研究设计与样本

  • III期随机对照试验ET743-SAR-3007的老年亚组事后分析,纳入131例≥65岁晚期脂肪肉瘤或平滑肌肉瘤患者。
  • 患者按2:1随机接受曲贝替定(n=94)或达卡巴嗪(n=37)静脉给药,每3周一次。

主要发现

  • 曲贝替定组中位治疗周期为4周期,达卡巴嗪组为2周期;曲贝替定组接受≥6周期治疗的比例为43%,达卡巴嗪组为23%(P=0.04)。
  • 曲贝替定组中位无进展生存期为4.9个月,达卡巴嗪组为1.5个月(HR=0.40,P=0.0002)。
  • 曲贝替定组中位总生存期为15.1个月,达卡巴嗪组为8.0个月(HR=0.72,P=0.18)。
  • 曲贝替定组客观缓解率为9%,达卡巴嗪组为3%(P=0.43)。
  • 曲贝替定在老年患者中的安全性特征与总体曲贝替定治疗人群相当。

关键数值与推荐

  • 老年亚组定义:年龄≥65岁。
  • 主要终点为总生存期,次要终点包括无进展生存期、至进展时间、客观缓解率、缓解持续时间、症状严重程度和安全性。

临床怎么用

  • 对于体能状态良好的老年晚期脂肪肉瘤或平滑肌肉瘤患者,曲贝替定可作为治疗选择之一。
  • 治疗期间需关注安全性,其安全性特征与总体人群相当。

局限性

  • 该分析为III期试验的事后亚组分析,老年亚组样本量较小(131例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk of toxicity associated with standard systemic therapies. Trabectedin has demonstrated improved disease control in a phase III trial (ET743-SAR-3007) of patients with advanced liposarcoma or leiomyosarcoma after failure of anthracycline-based chemotherapy. Since previous retrospective analyses have suggested that trabectedin has similar safety and efficacy outcomes regardless of patient age, we carried out a subgroup analysis of the safety and efficacy observed in elderly patients enrolled in this trial. PATIENTS AND METHODS: Patients were randomized 2 : 1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every-3-weeks. The primary end point was overall survival (OS); secondary end points were progression-free survival (PFS), time-to-progression, objective response rate (ORR), duration of response, symptom severity, and safety. A post hoc analysis was conducted in the elderly patient subgroup. RESULTS: Among 131 (trabectedin = 94; dacarbazine = 37) elderly patients, disease characteristics were well-balanced and consistent with those of the total study population. Treatment exposure was longer in patients treated with trabectedin versus dacarbazine (median four versus two cycles, respectively), with a significantly higher proportion receiving prolonged therapy (≥6 cycles) in the trabectedin arm (43% versus 23%, respectively; P = 0.04). Elderly patients treated with trabectedin showed significantly improved PFS [4.9 versus 1.5 months, respectively; hazard ratio (HR)=0.40; P = 0.0002] but no statistically significant improvement in OS (15.1 versus 8.0 months, respectively; HR = 0.72; P = 0.18) or ORR (9% versus 3%, respectively; P = 0.43). The safety profile for elderly trabectedin-treated patients was comparable to that of the overall trabectedin-treated study population. CONCLUSIONS: This subgroup analysis of the elderly population of ET743-SAR-3007 suggests that elderly patients with STS and good performance status can expect clinical benefit from trabectedin similar to that observed in younger patients. TRIAL REGISTRATION: www.clinicaltrials.gov, NCT01343277.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Jones RL, Demetri GD, Schuetze SM, et al. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018. PMID: 30084934. doi:10.1093/annonc/mdy253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。